Sana Biotechnology Inc (SANA) concluded trading on Wednesday at a closing price of $3.25, with 4.11 million shares of worth about $13.36 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -47.15% during that period and on January 29, 2025 the price saw a loss of about -4.69%. Currently the company’s common shares owned by public are about 223.11M shares, out of which, 122.70M shares are available for trading.
Stock saw a price change of -7.14% in past 5 days and over the past one month there was a price change of 91.18%. Year-to-date (YTD), SANA shares are showing a performance of 99.39% which decreased to -40.59% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.52 but also hit the highest price of $12.00 during that period. The average intraday trading volume for Sana Biotechnology Inc shares is 6.61 million. The stock is currently trading 10.85% above its 20-day simple moving average (SMA20), while that difference is up 29.36% for SMA50 and it goes to -35.13% lower than SMA200.
Sana Biotechnology Inc (NASDAQ: SANA) currently have 223.11M outstanding shares and institutions hold larger chunk of about 53.36% of that.
The stock has a current market capitalization of $725.63M and its 3Y-monthly beta is at 1.67. It has posted earnings per share of -$1.41 in the same period. It has Quick Ratio of 4.47 while making debt-to-equity ratio of 0.33. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for SANA, volatility over the week remained 10.64% while standing at 18.23% over the month.
Stock’s fiscal year EPS is expected to rise by 17.68% while it is estimated to increase by 27.22% in next year. EPS is likely to grow at an annualized rate of 17.56% for next 5-years, compared to annual growth of -83.13% made by the stock over the past 5-years.
On June 26, 2024, Rodman & Renshaw Initiated their recommendations, while on January 16, 2024, H.C. Wainwright Upgrade their ratings for the stock with a price target of $12. Stock get a Mkt outperform rating from JMP Securities on September 25, 2023.
